We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Guidance Eases Reporting of Adverse Events in EU Clinical Trials
Guidance Eases Reporting of Adverse Events in EU Clinical Trials
Sponsors of investigational drugs could see some relief from burdensome adverse event reporting requirements in the EU’s 2010 good pharmacovigilance practice law, thanks to a revised guideline issued last month by the European Medicines Agency.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor